AgeX Therapeutics reports FY2022 net loss of $10.5M; cash only $0.7M, substantial doubt about going concern

Serina Therapeutics, Inc.

2024-Q1 EPS reported $0.20 revenue$10,000

Net loss of $10.5M ($0.28 per share) in FY2022 vs $8.7M ($0.23) in FY2021.
Cash and restricted cash only $0.7M; owes Juvenescence $21.4M in loans.
Substantial doubt about ability to continue as a going concern for next 12 months.
Operating expenses fell to $7.0M from $8.2M; R&D decreased to $1.0M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Serina Therapeutics, Inc. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue Total revenues for the fourth quarter of 2022 were $8,000 as compared with $27,000 for the fourth quarter of 2021. Total, net income Net loss attributable to AgeX for the year ended December 31, 2022 was $10.5 million, EPS ($0.28) per share (basic and diluted).

Period: fourth quarter and fiscal year ended December 31, 2022
Revenue: Total revenues for the fourth quarter of 2022 were $8,000 as compared with $27,000 for the fourth quarter of 2021. Total
Net income: Net loss attributable to AgeX for the year ended December 31, 2022 was $10.5 million
EPS: ($0.28) per share (basic and diluted)
Result: reported results

Exact text from the filing

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-010315

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.